There are some skin conditions we're very familiar with: spots during adolescence, allergic rashes, sunburn. But others are ...

Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the ...

As Bobby noted, we are extremely excited about Ocular Rosacea. Because like DB, it is caused by Demodex mites and can impact how we look, feel and see. It can also be quickly and simply diagnosed ...

Another possible cause of rosacea is the increased presence of a common microscopic mite called Demodex folliculorum. This mite is more abundant on the skin of people with rosacea. According to ...

is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...

INDICATIONS AND USAGEXDEMVY is indicated for the treatment of Demodex blepharitis ... TP-04 for the potential treatment of Ocular Rosacea. About TP-05TP-05 is an investigational oral systemic ...

Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.

as Huff described additional research which identified peptides and neurotransmitters involved in neurovascular dysregulation and the role of Demodex mites in rosacea. When asked about the future ...